April 12, 2019

In Vivo

Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition

By Roger Longman

It is a world, at least the US corner of it, in which any common understanding of  drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?

read full article >